[Is short-course therapy enough at drug-resistant tuberculosis?]

Area of Science:

• Pulmonology
• Infectious Diseases
• Microbiology

Background:

• Tuberculosis drug resistance presents challenges in treatment protocol selection and duration.
• Physicians employ various strategies to manage tuberculosis drug resistance.
• Understanding treatment outcomes for non-MDR-TB is essential for effective patient management.

Purpose of the Study:

• To evaluate treatment regimens and outcomes for patients with non-multidrug-resistant tuberculosis (MDR-TB).
• To analyze the impact of different treatment protocols on patient success rates.
• To identify key factors influencing treatment success in non-MDR-TB cases.

Main Methods:

• Retrospective analysis of 167 culture-positive patients diagnosed with non-MDR-TB between 2008-2010.
• Evaluation of patient demographics, previous TB treatments, bacteriological data, drug resistance patterns, and treatment outcomes.
• Analysis of treatment success rates based on different therapeutic regimens and patient groups (new vs. recurrent cases).

Main Results:

• The study included 167 patients (70.1% male, mean age 42.35 years).
• Isoniazid resistance was most common (44.9%), followed by rifampicin resistance (6.6%).
• Overall treatment success was achieved in 81.4% of patients; however, 19.8% did not complete treatment.

Conclusions:

• No significant difference in treatment outcomes was observed among patients who completed their treatment for non-MDR-TB.
• Effective monitoring of non-MDR-TB patients is vital to prevent the development of MDR-TB.
• Adherence to treatment protocols and completion are critical for successful tuberculosis management.